Posted by Gary Schwitzer in Uncategorized
Some time off, some business travel, talk in Barcelona – so no new postings until October 3.
Comments are closed.
Better than a competing piece by Reuters but still a little short on some details about this asthma drug study.
An adequate summary of this asthma drug trial’s design doesn’t make up for the overly optimistic tone about the drug’s future. A New York Times story was better.
This story focuses on a family that may have a rare genetic mutation that increases their risk of heart disease. Unfortunately, the “rare” part wasn’t mentioned until 1,600 words into this 2,100 word story.
We will not display your name or e-mail address on the site, nor will we share youre-mail address with any third parties.
Copyright © 2013 Health News Review